Amgen Inc. (AMGN) $340.90
Amgen finds itself at a critical juncture, with deeply oversold technicals suggesting a bounce is imminent, yet a constrained analyst consensus target curbs enthusiasm for a high-conviction entry.
52-wk High $391.29
π Investment Snapshot
- π° Currently trading at $340.90, Amgen holds a $183.8B market cap with a TTM P/E of 23.96x.
- π Q4 2025 revenue hit $9.87B, delivering EPS of $2.45.
- π The stock’s RSI at 27.1 screams oversold, hinting at an imminent technical bounce.
- π― Analysts maintain a “Buy” consensus, targeting $350.76 for a modest 2.89% upside.
Amgen’s technical indicators, particularly an RSI of 27.1 and a strong Technical Confluence Score of 70, signal a deeply oversold condition ripe for a bounce. However, the limited upside to the current analyst consensus target of $350.76 prevents a high-conviction buy call for long-term investors. We await a clearer fundamental catalyst or a deeper retracement to improve the risk/reward profile.
| π Entry Zone | Below $335.00 | π Stop-Loss | $330.00 |
| π Adjust If | A significant upward revision in analyst price targets or a confirmed fundamental catalyst emerges. | ||
The Investment Case β Why Now?
Amgen’s recent price action has seen a 7.7% decline over the past month, pushing its RSI into deeply oversold territory at 27.1. This technical weakness, combined with the stock trading 12.9% below its 52-week high, presents a potential short-term bounce opportunity for agile traders. The robust Technical Confluence Score of 70 further underscores the technical setup for a reversal.
The primary challenge to a sustained rally remains the limited upside to the consensus analyst target of $350.76, which offers only a modest 2.89% return from current levels. This suggests that while a technical rebound is likely, the broader analyst community does not yet foresee significant long-term appreciation without new fundamental drivers. Investors must weigh the immediate technical opportunity against this constrained long-term outlook.
π€ Given the strong oversold technicals, are you willing to overlook the modest consensus price target for a potential short-term bounce, or will you wait for a more compelling fundamental catalyst?
π’ Company Overview
| Detail | Value |
|---|---|
| Company | Amgen Inc. |
| Ticker / Exchange | AMGN / NYSE |
| Sector / Industry | Healthcare / Drug Manufacturers – General |
| CEO | Robert A. Bradway |
| Founded / HQ | 1980 / Thousand Oaks, CA |
π Price Action & Technicals
Dead Cross
Inside VA
A buy-side sweep at $374.25 on March 3rd, 2026, potentially indicating exhaustion of buying power at higher levels.
Amgen’s price action reveals a stock under significant pressure, with the current $340.90 trading well below its 50-day SMA of $362.29. This breakdown below a key moving average signals a bearish short-term trend, reinforcing the recent 7.7% decline over the past month. The stock remains 12.9% off its 52-week high, highlighting the extent of the recent correction.
The RSI at 27.1 screams deeply oversold, a condition that historically precedes at least a temporary bounce. However, the MACD's dead cross (-5.53 below signal -4.21) and a strong bearish trend indicated by ADX (46.5) with -DI (35.6) dominating +DI (13.4) suggest underlying selling momentum remains robust. This creates a technical divergence: oversold conditions versus persistent bearish trend strength.
From a volume perspective, the stock is currently trading within its Value Area ($271.03-$351.2), but above the Volume Profile's Point of Control ($288.57). The Anchored VWAP from May 2025 at $313.48 sits significantly below the current price, indicating that many longer-term participants are still in profit, which could limit immediate strong support from that level.
Volume is running well below average at 58% of the 20-day average, suggesting that the recent price decline lacks strong conviction from either buyers or sellers, potentially setting the stage for volatility. The recent buy-side sweep at $374.25 on March 3rd, followed by a sharp decline, could signal a capitulation event for buyers at higher prices, while sell-side sweeps at $382.47 and $380.58 in late February indicate prior demand zones were breached.
β Peer P/E Comparison
| Ticker | Company | P/E (TTM) |
|---|---|---|
| AMGN | Amgen Inc. | 23.96x |
| JNJ | Johnson & Johnson | 22.5x |
| MRK | Merck & Co. | 28.1x |
| PFE | Pfizer Inc. | 18.7x |
| S&P 500 | Index Average | 21.0x |
π° Earnings Deep Dive
| Period | Revenue | EPS | YoY |
|---|---|---|---|
| 2025-12-31 | $9.87B | $2.45 | |
| 2025-09-30 | $9.56B | $5.93 | |
| 2025-06-30 | $9.18B | $2.65 | |
| 2025-03-31 | $8.15B | $3.20 |
Amgen consistently generates substantial free cash flow, with the latest quarter reporting $1.0 billion. This robust cash generation underpins its ability to fund research and development, execute strategic acquisitions, and maintain a generous 2.94% dividend yield.
π Growth Drivers β What Moves the Stock
- Biosimilars Portfolio Expansion π’ Upside Surprise β Amgen continues to expand its biosimilar offerings, which provide a significant growth runway as patents expire on blockbuster biologics. This strategy diversifies revenue streams and captures market share in cost-conscious healthcare environments.
- Robust Pipeline Innovation π’ Upside Surprise β The company boasts a strong pipeline, particularly in oncology, cardiovascular, and inflammation. Key late-stage assets, if approved, could significantly boost future revenue and offset potential declines from mature products.
- Emerging Obesity Drug Market π’ Upside Surprise β While not a leader, Amgen’s early-stage obesity drug candidates represent a potential high-growth area. Positive clinical readouts could unlock substantial long-term value in this rapidly expanding market.
π€ How much weight do you assign to Amgen’s biosimilar growth strategy versus its pipeline innovation in determining its long-term value proposition?
π¦ Smart Money & Institutional Positioning
13F Holdings
| Institution | Shares (K) |
|---|---|
| Vanguard Group Inc | 54,838 |
| Blackrock Inc. | 47,396 |
| State Street Corporation | 30,591 |
| Capital World Investors | 23,097 |
| Capital International Investors | 18,186 |
| Morgan Stanley | 15,744 |
| Geode Capital Management, LLC | 14,303 |
| Charles Schwab Investment Management, Inc. | 11,811 |
| Primecap Management Company | 8,904 |
| Wells Fargo & Company | 7,110 |
Holdings reflect most recent 13F (45-day lag).
Insider Transactions
| Name | Title | Date | Type | Shares |
|---|---|---|---|---|
| BRADWAY ROBERT A | Chief Executive Officer | Mar 4, 2026 | Award | 119,782 |
| BRADWAY ROBERT A | Chief Executive Officer | Mar 3, 2026 | Award | 42,657 |
| GRAHAM JONATHAN P | General Counsel | Mar 3, 2026 | Award | 10,723 |
| MILLER DEREK | Officer | Mar 3, 2026 | Award | 3,484 |
| BUSCH MATTHEW C. | Officer | Mar 3, 2026 | Award | 938 |
| KHOSLA RACHNA | Officer | Mar 3, 2026 | Award | 1,876 |
| SANTOS ESTEBAN | Officer | Mar 3, 2026 | Award | 11,259 |
| REESE DAVID M. | Chief Technology Officer | Mar 3, 2026 | Award | 12,063 |
Short Interest
| Short % Float | Days to Cover |
|---|---|
| 0.0% | 6.1 |
β Key Risk Factors
π― Guidance & Wall Street View
| High Target | Mean Target | Low Target | Analysts | Consensus |
|---|---|---|---|---|
| $432.0 | $350.76 | $200.0 | 29 | Buy |
| Firm | Rating | Target | Date | Action |
|---|---|---|---|---|
| Jefferies | Hold | Mar 2026 | Initiates | |
| Barclays | Equal-Weight | Feb 2026 | Initiates | |
| Wells Fargo | Equal-Weight | Feb 2026 | Maintains | |
| Piper Sandler | Overweight | Feb 2026 | Maintains | |
| Freedom Broker | Hold | Feb 2026 | Downgrades | |
| Argus Research | Buy | Feb 2026 | Maintains | |
| Guggenheim | Neutral | Feb 2026 | Maintains | |
| Citigroup | Neutral | Feb 2026 | Maintains |
The consensus “Buy” rating from 29 analysts, with a mean target of $350.76, suggests a generally positive outlook. However, the modest 2.89% upside to the mean target indicates that much of Amgen’s near-term potential may already be priced in, prompting caution for new entries seeking substantial capital appreciation.
π Bull vs Bear β Probability-Weighted Scenarios
π Bull Case
- Deeply oversold RSI (27.1) signals an imminent technical bounce.
- Robust pipeline and biosimilar growth provide future revenue diversification and upside potential.
π Base Case
Our base case assumes Amgen navigates patent expirations effectively, leveraging its pipeline and biosimilar portfolio for modest, consistent growth. The current valuation reflects these known factors, with limited immediate upside without new catalysts.
π» Bear Case
- Failure of key pipeline assets or intensified competition from biosimilars could erode revenue.
- Increased regulatory pressure on drug pricing or a sustained market downturn could depress valuation.
π― Investor Action Plan β By Profile
Despite the deeply oversold RSI, the lack of a strong immediate catalyst and limited upside to consensus target suggest staying on the sidelines. Look for a reclaim of $345 with increased volume for a short-term bounce play, with a tight stop below $338.
For position investors, the current setup is intriguing due to oversold conditions, but the risk/reward is not compelling enough for a high-conviction entry. Patiently wait for a deeper pullback towards the Anchored VWAP at $313.48 or a significant fundamental catalyst to emerge, allowing for a more favorable entry point.
Long-term investors holding Amgen should maintain their position, as the company’s robust pipeline and consistent cash flow generation support its fundamental thesis. However, new capital should wait for a more attractive entry point that offers a better margin of safety and higher potential upside, perhaps on a dip towards the lower end of its historical trading range.
β Investor FAQ β People Also Ask
Q: Why is Amgen’s stock price declining despite its strong fundamentals?
Amgen’s recent 7.7% decline over the past month appears to be driven by broader market volatility (VIX at 26.28) and sector-specific pressures, rather than a breakdown in its core business. Technical factors like a MACD dead cross also contribute to the downward momentum, despite its solid cash flow generation.
Q: Is Amgen currently undervalued given its oversold RSI?
While the RSI at 27.1 screams oversold, suggesting a technical bounce is likely, the stock’s P/E of 23.96x is slightly above the S&P 500 average. Furthermore, the analyst consensus target of $350.76 offers only 2.89% upside, indicating that analysts don’t see significant undervaluation for a sustained rally at current prices.
Q: What are the key risks to Amgen’s future growth?
Amgen faces several key risks, including patent expirations on blockbuster drugs, intense competition from biosimilars, and the inherent risks of pipeline development and clinical trial failures. Additionally, regulatory and pricing pressures in the pharmaceutical sector remain a constant concern, potentially impacting future profitability.
π For real-time updates and advanced charting tools,
π Disclaimer
This analysis is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with a financial professional before making any investment decisions. The views expressed are based on available data and market conditions as of the date of publication and may change without notice.
All active positions and their real-time performance are tracked on our Investment Log.
#AMGN #Amgen #USStocks #StockAnalysis #Healthcare #Pharma #TechnicalAnalysis #Investment